Commentary: Quantifying the Human Mortality Costs of Patent-Based Intellectual Property: How Many Premature Deaths are Due to Patents?
摘要
This comment reviews he article, “Quantifying the HumanMortality Costs of Patent-based Intellectual Property: How Many PrematureDeaths are due to Patents?”, by Joshua M. Pearce and argues that the analysisis overly simplistic.While theaffordability of medicine is a troubling challenge, one must examine thebenefits of intellectual property protection as well as the costs in order toprovide meaningful analysis.By failingto do so the author does us all a disservice by blaming the IP system, anobvious target.The truth is far morenuanced and serious readers deserve an analysis that reflects this and shedslight on the subtleties of the problem rather than turning to an easyscapegoat.
Keywords: intellectual property, patents, insulin